14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XPH vs XHE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, SPDR S&P Health Care Equipment ETF (XHE) is the stronger overall head-to-head candidate over SPDR S&P Pharmaceuticals ETF (XPH) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). XPH carries a Unified Composite Score of 41.0/100 (SELL) at $65.58 (N/M Forward P/E, N/A operating margin), whereas XHE carries 46.8/100 (HOLD) at $93.83 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XPH vs XHE. Trailing 12-month operating profitability (XPH N/A vs XHE N/A) and valuation multiples (XPH N/M vs XHE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XPH vs XHE Key Questions & Quantitative Answers
As of Nov 16, 2026, SPDR S&P Health Care Equipment ETF (XHE) is the stronger overall head-to-head candidate over SPDR S&P Pharmaceuticals ETF (XPH) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). XPH carries a Unified Composite Score of 41.0/100 (SELL) at $65.58 (N/M Forward P/E, N/A operating margin), whereas XHE carries 46.8/100 (HOLD) at $93.83 (N/M Forward P/E, N/A operating margin). Technically, XPH sits in a Neutral phase (RSI 51.5, UNCLASSIFIED options structure) and XHE sits in a Neutral phase (RSI 51.1, UNCLASSIFIED options structure).
XPH and XHE split Growth & Scale metrics: XPH posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with XHE at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, XPH generates N/A in USD-normalized revenue versus N/A for XHE. In operating R&D and SG&A reinvestment, XPH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XHE.
XPH and XHE trade at balanced relative valuation multiples. XPH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas XHE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XPH (N/A ROE) versus XHE (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, XPH carries 20.9% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 32% Vol realized risk). By comparison, XHE carries 252.7% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 39% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.